Shares of Arbutus Biopharma (NASDAQ:ABUS) have received an average recommendation of “Hold” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.38.
A number of analysts recently issued reports on ABUS shares. ValuEngine raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a research report on Monday. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. BidaskClub raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Wedbush downgraded Arbutus Biopharma from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $6.00 in a research report on Monday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Spark Investment Management LLC boosted its stake in shares of Arbutus Biopharma by 98.3% in the fourth quarter. Spark Investment Management LLC now owns 23,000 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 11,400 shares during the period. Citadel Advisors LLC bought a new stake in Arbutus Biopharma during the fourth quarter worth $146,000. Two Sigma Investments LP bought a new stake in Arbutus Biopharma during the fourth quarter worth $215,000. Goldman Sachs Group Inc. bought a new stake in Arbutus Biopharma during the fourth quarter worth $275,000. Finally, Vanguard Group Inc. lifted its stake in Arbutus Biopharma by 2.7% during the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 2,035 shares during the last quarter. 62.12% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:ABUS traded down $0.10 during midday trading on Thursday, reaching $5.05. The company had a trading volume of 137,795 shares, compared to its average volume of 179,873. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.85 and a current ratio of 8.85. The company has a market cap of $278.10, a P/E ratio of -2.82 and a beta of 1.06. Arbutus Biopharma has a 1-year low of $3.20 and a 1-year high of $8.25.
Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.51). The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $0.70 million. Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. equities analysts predict that Arbutus Biopharma will post -1.7 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/05/arbutus-biopharma-abus-given-consensus-recommendation-of-hold-by-brokerages.html.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.